Abstract 1139
Background
In two retrospective studies we analyzed endothelial-derived nitric oxide synthase (eNOS) and angiopoietin-2 (ANGPT2) polymorphisms, and patients with eNOS-786CC+TC genotype and ANGPT2rs55633437 GG genotypes had significantly higher median PFS and OS compared to those with other genotypes. On the basis of these preliminary results, our aim was to validate in a prospective study these data in patients with HCC treated with sorafenib (S).
Methods
The primary outcomes were PFS. 160 total sample size was planned with the aim to confirm a HR of 0.58. Event-time distributions were estimated using the Kaplan-Meier method and survival curves were compared using the log-rank test
Results
165 patients were prospectively enrolled in the study between 03/2015 and 06/2018. Median OS was 13.1 months and median PFS was 4.2 months. We confirmed that eNOS-786 CC+CT genotype was significantly associated with a higher median PFS (2.4 vs 5.9 months, HR 0.43, 95% CI 0.26-0.70 p = 0.0007) and OS (15.7 vs 8.6 months, HR 0.38, 95% CI 0.24-0.60 p < 0.0001) than the other genotypes. We did not confirm that ANGPT2rs55633437 GG genotypes were significantly associated with a lower median OS (p = 0.55) and PFS (p = 0.13). No differences were found between eNOS-786 TTand eNOS-786 CT/CCgenotypes in terms of disease control rate and best response. No correlations were found between eNOS polymorphisms and toxicity. Following adjustment for clinical covariates positive in univariate analzsis, multivariate analysis confirmed eNOS as the only independent prognostic factor predicting OS (p = 0.0072). After progression to S in all population we highlight that patients with the eNOS-786 CC+CT genotype was significantly associated with a lower median OS (HR 0.56, p = 0.03) and a trend was found for patients treated with regorafenib (HR 0.13 p = 0.057).
Conclusions
Our Italian multicenter, prospective study met its primary and secondary end points, and we confirmed that eNOS-786 CC+CT genotype may be capable of identifying a subset of HCC patients who have a higher median OS and PFS. For the first time in ten years of sorafenib research our study confirms the prognostic role of a biological marker in a prospective study.
Clinical trial identification
NCT02786342.
Editorial acknowledgement
Legal entity responsible for the study
University of Modena.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract